Iain Robert McGill
Directeur Général chez Jazz Pharmaceuticals Germany GmbH
Profil
Iain Robert McGill is currently the Chief Executive Officer & Director at Quell Therapeutics Ltd.
and the Managing Director at Jazz Pharmaceuticals Germany GmbH.
Previously, he served as an Independent Director at Otonomy, Inc. from 2016 to 2023, Vice President & Global Business Manager at Wyeth LLC from 2006 to 2009, Chief Commercial Officer at EUSA Pharma, Inc. from 2012 to 2014, Chief Commercial Officer at Jazz Pharmaceuticals UK Ltd.
from 2011 to 2012, Senior Vice President-Jazz Pharmaceuticals Europe at Jazz Pharmaceuticals Plc from 2012 to 2019, and Chief Commercial Officer at Eusa Pharma Europe Ltd.
from 2010 to 2012.
He obtained his undergraduate degree from the University of London.
Postes actifs de Iain Robert McGill
| Sociétés | Poste | Début |
|---|---|---|
Jazz Pharmaceuticals Germany GmbH
 Jazz Pharmaceuticals Germany GmbH Pharmaceuticals: MajorHealth Technology Part of Jazz Pharmaceuticals Plc, Jazz Pharmaceuticals Germany GmbH is a company committed to advancing clinical knowledge through various types of research, including non-interventional studies. The company is based in Munich, Germany. The company adheres to established regulations, industry best practices, and internal policies to ensure the integrity of their sponsored research. Jazz Pharmaceuticals Germany is focused on improving patients' lives by developing and commercializing products that address unmet medical needs. The CEO of the company is Iain Robert McGill. | Directeur Général | - |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Directeur Général | - |
Anciens postes connus de Iain Robert McGill
| Sociétés | Poste | Fin |
|---|---|---|
| OTONOMY | Directeur/Membre du Conseil | 15/02/2023 |
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01/01/2019 |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Corporate Officer/Principal | 01/03/2014 |
Jazz Pharmaceuticals UK Ltd.
 Jazz Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom. | Corporate Officer/Principal | 01/06/2012 |
| Eusa Pharma Europe Ltd. | Corporate Officer/Principal | 01/06/2012 |
Formation de Iain Robert McGill
| University of London | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| Entreprise privées | 7 |
|---|---|
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Health Technology |
Jazz Pharmaceuticals UK Ltd.
Jazz Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom. | Health Technology |
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
| Eusa Pharma Europe Ltd. | |
Jazz Pharmaceuticals Germany GmbH
Jazz Pharmaceuticals Germany GmbH Pharmaceuticals: MajorHealth Technology Part of Jazz Pharmaceuticals Plc, Jazz Pharmaceuticals Germany GmbH is a company committed to advancing clinical knowledge through various types of research, including non-interventional studies. The company is based in Munich, Germany. The company adheres to established regulations, industry best practices, and internal policies to ensure the integrity of their sponsored research. Jazz Pharmaceuticals Germany is focused on improving patients' lives by developing and commercializing products that address unmet medical needs. The CEO of the company is Iain Robert McGill. | Health Technology |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |